Dendritic cell therapy: Personalized immunotherapy for cancer

What is Dendritic Cell Therapy?

Dendritic Cell Therapy is a type of immunotherapy that uses the body’s dendritic cells, which are immune cells responsible for detecting and presenting antigens, to trigger a targeted immune response against diseases, especially cancer.

 In this treatment, dendritic cells are taken from the patient, exposed to specific antigens in a laboratory, and then returned to the patient’s body. Once reintroduced, these cells activate T-cells and coordinate an immune attack against abnormal or malignant cells, enhancing the body’s natural defenses while reducing harm to healthy tissue.

How Dendritic Cell Therapy Works in cancer treatment?

In cancer treatment, Dendritic Cell Therapy helps the immune system recognize and attack cancer cells more effectively. In simple terms, the therapy “trains” your immune system to spot tumors and respond to them.

• Targeting Cancer Cells: The therapy guides immune cells to identify specific markers found on cancer cells, helping the body distinguish them from healthy cells.

• Boosting Immune Response: Once trained, your immune system can mount a stronger and more precise attack on tumor cells, which may slow their growth and support other treatments.

• Personalized Approach: Because the therapy is tailored to each patient, it works specifically with your immune system, minimizing side effects while maximizing effectiveness.

• Supportive Role: Dendritic Cell Therapy often complements other treatments like surgery, chemotherapy, or immunotherapy, improving overall outcomes and helping the body respond more efficiently.

Clinical applications of Dendritic Cell Therapy in oncology

Dendritic Cell Therapy (DCT) has shown the most advanced therapeutic potential in oncology. It represents a form of personalized cancer immunotherapy designed to activate tumor-specific cytotoxic T lymphocytes capable of targeting malignant cells with minimal toxicity.

 Below are the primary cancer types where dendritic cell-based vaccines have been clinically applied.

Melanoma

Melanoma is an aggressive type of skin cancer that often spreads if not treated early. Dendritic Cell Therapy is used to help the immune system recognize and destroy melanoma cells. In this treatment, special immune cells (dendritic cells) are taken from the patient, trained in the laboratory to detect melanoma antigens, and then injected back into the body. This approach has shown good potential in slowing tumor progression and improving long-term disease control, especially when combined with other immunotherapies.

Prostate Cancer

Prostate cancer is the first malignancy with an FDA-approved dendritic cell therapy. The autologous vaccine Sipuleucel-T (Provenge) has been approved for metastatic castration-resistant prostate cancer. This therapy activates the patient’s dendritic cells against prostatic acid phosphatase (PAP),a tumor-associated antigen, resulting in delayed disease progression and improved overall survival.

 Glioblastoma Multiforme (GBM)

GBM is one of the most aggressive primary brain tumors, and survival rates remain poor despite surgery, radiotherapy, and chemotherapy. Personalized dendritic cell vaccines created from the patient’s own tumor lysate have shown the ability to stimulate immune activity within the brain tumor microenvironment, extend survival, and delay recurrence. This approach is now part of several phase III clinical trials.

Non-Small Cell Lung Cancer (NSCLC)

In lung cancer, dendritic cell therapy has been administered as a therapeutic cancer vaccine to prime T-cell responses against tumor antigens such as WT1 and MUC1. Clinical trials show improved immune activity and longer disease stabilization when combined with immune checkpoint inhibitors (e.g. pembrolizumab). It is also explored as maintenance therapy following chemotherapy.

Pancreatic Cancer

Pancreatic adenocarcinoma is known for its poor response to conventional therapy and highly immunosuppressive tumor microenvironment. Dendritic cell vaccines loaded with tumor antigens have been used experimentally to induce cytotoxic T-cell activity. When combined with chemotherapy agents such as gemcitabine, DCT has led to improved disease control in early studies.

Ovarian Cancer

Ovarian cancer often presents at an advanced stage and has a high recurrence rate. Dendritic cell therapy is being investigated as an immunotherapeutic strategy to reduce relapse by targeting antigens such as NY-ESO-1 and HER2/neu. When used alongside PARP inhibitors or anti-angiogenic therapy, it has shown enhanced tumor-specific immune responses.

Renal Cell Carcinoma (RCC)

RCC is a highly immunogenic tumor, making it a promising target for dendritic cell vaccination. Clinical trials have demonstrated that DCT can activate tumor-specific T-cells and improve survival, especially when used after surgical removal of the primary tumor to prevent recurrence.

Colorectal Cancer

In metastatic colorectal cancer, dendritic cell vaccines are used to stimulate immune responses against carcinoembryonic antigen (CEA). While modest as monotherapy, efficacy improves significantly when combined with chemotherapy or checkpoint inhibitors.

Breast Cancer

Dendritic cell-based vaccines are being tested in triple-negative and HER2-positive breast cancer. Early-phase studies have shown tumor regression in some patients, particularly when vaccines are administered in the neoadjuvant setting to eliminate residual disease.

Leukemia and Lymphoma

In hematological malignancies, dendritic cell therapy is used to induce long-term immune surveillance. It is especially beneficial post stem cell transplantation, where it helps trigger graft-versus-leukemia effects while reducing relapse risk and minimizing the need for donor lymphocyte infusion.

Who can receive dendritic cell therapy?

Dendritic Cell Therapy is not suitable for everyone, but it can be considered for patients with certain types of cancer or specific treatment needs. Typically, candidates include:

• Patients with cancer that can be targeted by the immune system: DCT works best when the immune system can recognize and respond to tumor cells. It is often used in cancers such as melanoma, prostate cancer, lung cancer, ovarian cancer, and some blood cancers.
  

• Patients looking for a personalized treatment: Because DCT uses your own immune cells, it is tailored to your body and your cancer, making it suitable for patients interested in targeted immunotherapy.
  

• Patients who can tolerate the therapy: DCT is generally well tolerated and safe, but doctors evaluate your overall health, medical history, and other treatments to ensure it is appropriate for you.

• Patients who may combine treatments: DCT is often used alongside other treatments such as surgery, chemotherapy, or checkpoint inhibitors. Patients who are candidates for combination therapy may benefit most.
  

• Those participating in clinical trials: For some cancers, DCT is still considered experimental. Participation in clinical trials may provide access to the therapy under careful medical supervision.

Effectiveness of Dendritic Cell Therapy in cancer

Dendritic cell therapy has emerged as a promising immunotherapeutic approach for various types of cancer. Its effectiveness, however, varies depending on the cancer type, disease stage, and whether it is combined with other treatments. 

According to a comprehensive review from the National Institutes of Health, dendritic cell therapy has shown clinical response rates generally ranging from 10% to 50% across different cancers, improving progression-free and overall survival rather than providing outright cures (according to PMC: Dendritic Cell and Cancer Therapy, 2023).​

Effectiveness on MeLanoma

In melanoma patients, dendritic cell therapy achieves disease stabilization in approximately 30-50% of cases, with partial or complete tumor responses seen in about 10-15%, especially when combined with immune checkpoint inhibitors (according to ScienceDirect: Dendritic Cell-Based Vaccines, 2025). 

Effectiveness on glioblastoma

 clinical trials have reported median survival rates extended to 18-24 months, compared to 12-15 months with standard care, with some patients achieving long-term survival beyond three years (according to Nature: Cytokine-Overexpressing Dendritic Cells for Cancer, 2024).​

Effectiveness on prostate cancer 

Prostate cancer patients receiving dendritic cell therapy show immune activation in up to 70% of cases, often reflected in lowered PSA levels, marking a positive response to treatment (according to Treatment in Germany, 2025). Similarly, in non-small cell lung cancer and renal cell carcinoma, disease control rates reach 40-50% and 30-40%, respectively, with response rates typically in the 10-20% range (according to Frontiers in Immunology, 2024).​

Effectiveness on cervical cancer 

More strikingly, dendritic cell therapy in cervical cancer has demonstrated response rates between 50-65%, accompanied by improved quality of life and survival outcomes (according to Booking Health, 2025).

Effectiveness on pancreatic cancer

 in pancreatic cancer, adjuvant dendritic cell-based immunotherapy has yielded clinically meaningful improvements in recurrence-free survival, underscoring its potential as a complementary treatment (according to Cancer Therapy Advisor, 2024).​

In summary, while dendritic cell therapy is not yet a definitive cure for most cancers, it offers a valuable addition to cancer treatment regimens by stimulating the patient's immune system to target tumors more effectively. 

Its efficacy is expected to improve further with ongoing research and combination strategies, making it a powerful tool in personalized cancer therapy (according to ASCO Publications, 2024).​

Steps of Dendritic Cell Therapy in cancer

Dendritic Cell Therapy is usually given in a series of steps, designed to help your immune system target cancer cells effectively. Here’s what typically happens:

1. Blood Collection
   A small amount of your blood is taken to collect immune cells called dendritic cells. This is similar to a standard blood test.

2. Cell Preparation in the Lab
   The dendritic cells are carefully treated in a laboratory to “teach” them to recognize cancer cells. This training involves exposing the cells to cancer markers so they can alert the immune system.

3. Injection Back into the Body
   Once the dendritic cells are trained, they are returned to your body through an injection, usually under the skin or into a vein.

4. Immune Activation
   The injected dendritic cells help your immune system recognize cancer cells and respond more effectively. Your body’s natural defenses are now better equipped to find and attack tumors.

5. Monitoring and Follow-up
   After therapy, your doctor will monitor your immune response and overall health. This may include regular blood tests, scans, and check-ups to track how well the treatment is working.

6. Combination with Other Treatments
   Dendritic Cell Therapy is often used alongside other treatments like chemotherapy, surgery, or immunotherapy to improve results and support your recovery.

Possible side effects of Dendritic Cell Therapy

Dendritic Cell Therapy is generally safe and well tolerated. Most patients experience only mild and temporary side effects, which are usually manageable:

• At the Injection Site: You might notice slight redness, swelling, or tenderness where the therapy is given. These effects usually fade within a day or two.
• Mild Flu-like Symptoms: Some patients feel tired, have a low-grade fever, or experience body aches for a short time after the treatment. These usually pass quickly.
• Headache or Mild Nausea: A few people may have a mild headache or feel slightly nauseated, which generally resolves on its own.
• Rare Immune Reactions: Serious allergic or immune responses are uncommon, but your medical team will monitor you carefully to ensure your safety.

Overall, side effects are much milder than those associated with chemotherapy or radiation, making dendritic cell therapy a gentle option that supports your immune system.

What to expect before, during, and after dendritic cell therapy

Dendritic Cell Therapy is designed to support your immune system in fighting cancer. Understanding what happens at each stage can help you feel more prepared and comfortable throughout the process.

Before treatment

1. Medical consultation and evaluation: Your healthcare team will review your medical history, current health, and previous treatments. This ensures DCT is suitable for you and helps plan your personalized treatment schedule.
   

2. Blood collection: A small blood sample is taken to collect your dendritic cells. This procedure is similar to a routine blood test and usually takes less than an hour.
   

3. Cell preparation: The collected cells are sent to a specialized laboratory, where they are “trained” to recognize markers specific to your cancer. This step prepares your immune system to better identify and target tumor cells once the cells are returned to your body.
   

During treatment

1. Injection of trained dendritic cells: The lab-prepared dendritic cells are returned to your body through an injection, often under the skin or into a vein. This process is usually quick and comfortable.
   

2. Monitoring for immediate reactions: Healthcare staff will observe you during and shortly after the injection to ensure you are safe and comfortable. Mild side effects like redness at the injection site or slight fatigue may occur, but serious reactions are rare.
   

3. Multiple sessions (if needed): Depending on your treatment plan, you may receive several injections over weeks or months. Your medical team will guide you on the schedule and what to expect with each session.
   

After treatment

1. Follow-up visits: Your doctor will schedule regular check-ups to monitor your health and track how your immune system is responding. This may include blood tests, scans, or other assessments.
   

2. Combination with other therapies: DCT often works alongside surgery, chemotherapy, or other immunotherapies. Your healthcare team will coordinate all treatments to maximize benefits.
   

3. Managing side effects: Any mild side effects, such as fatigue or low-grade fever, are managed with supportive care. Your medical team will provide guidance on how to stay comfortable and safe at home.
   

4. Ongoing immune support: In some cases, booster injections or additional monitoring may be recommended to help maintain your immune system’s response against cancer over time.

Looking ahead: the future of dendritic cell therapy 

Dendritic Cell Therapy is a promising, personalized approach that helps the body’s immune system recognize and fight cancer more effectively. While it is not a definitive cure for all cancers, it can complement conventional treatments, improve immune responses, and offer patients a therapy with fewer side effects.

With ongoing research and clinical trials, dendritic cell therapy continues to advance, providing hope for more effective and targeted cancer care in the future.